Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer

Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported to cause multidrug and radiation resistance - their...

Full description

Bibliographic Details
Main Authors: Abdullah, Nurul Akmaryanti, Inman, Martyn, Moody, Christopher J., Storr, Sarah J., Martin, Stewart G.
Format: Article
Language:English
Published: Kluwer Academic Publishers 2021
Online Access:http://psasir.upm.edu.my/id/eprint/96589/
http://psasir.upm.edu.my/id/eprint/96589/1/ABSTRACT.pdf
_version_ 1848862401884061696
author Abdullah, Nurul Akmaryanti
Inman, Martyn
Moody, Christopher J.
Storr, Sarah J.
Martin, Stewart G.
author_facet Abdullah, Nurul Akmaryanti
Inman, Martyn
Moody, Christopher J.
Storr, Sarah J.
Martin, Stewart G.
author_sort Abdullah, Nurul Akmaryanti
building UPM Institutional Repository
collection Online Access
description Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported to cause multidrug and radiation resistance - their inhibition may therefore improve therapeutic efficacy. Novel indolequinone compounds have been shown, in pancreatic cancer models, to inhibit thioredoxin reductase activity and exhibit potent anticancer activity. The present study evaluates, using in vitro breast cancer models, the efficacy of a novel indolequinone compound (IQ9) as a single agent and in combination with ionising radiation using a variety of endpoint assays including cell proliferation, clonogenic survival, enzyme activity, and western blotting. Three triple-negative breast cancer (MDA-MB-231, MDA-MB-468, and MDA-MB-436) and two luminal (MCF-7 and T47D) breast cancer cell lines were used. Results show that treatment with IQ9 significantly inhibited thioredoxin reductase activity, and inhibited cell growth and colony formation of breast cancer cells with IC50 values in the low micromolar ranges. Enhanced radiosensitivity of triple-negative breast cancer cells was observed, with sensitiser enhancement ratios of 1.20-1.43, but with no evident radiosensitisation of luminal breast cancer cell lines. IQ9 upregulated protein expression of thioredoxin reductase in luminal but not in triple-negative breast cancer cells which may explain the observed differential radiosensitisation. This study provides important evidence of the roles of the thioredoxin system as an exploitable radiobiological target in breast cancer cells and highlights the potential therapeutic value of indolequinones as radiosensitisers.
first_indexed 2025-11-15T13:16:27Z
format Article
id upm-96589
institution Universiti Putra Malaysia
institution_category Local University
language English
last_indexed 2025-11-15T13:16:27Z
publishDate 2021
publisher Kluwer Academic Publishers
recordtype eprints
repository_type Digital Repository
spelling upm-965892023-01-11T07:29:33Z http://psasir.upm.edu.my/id/eprint/96589/ Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer Abdullah, Nurul Akmaryanti Inman, Martyn Moody, Christopher J. Storr, Sarah J. Martin, Stewart G. Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported to cause multidrug and radiation resistance - their inhibition may therefore improve therapeutic efficacy. Novel indolequinone compounds have been shown, in pancreatic cancer models, to inhibit thioredoxin reductase activity and exhibit potent anticancer activity. The present study evaluates, using in vitro breast cancer models, the efficacy of a novel indolequinone compound (IQ9) as a single agent and in combination with ionising radiation using a variety of endpoint assays including cell proliferation, clonogenic survival, enzyme activity, and western blotting. Three triple-negative breast cancer (MDA-MB-231, MDA-MB-468, and MDA-MB-436) and two luminal (MCF-7 and T47D) breast cancer cell lines were used. Results show that treatment with IQ9 significantly inhibited thioredoxin reductase activity, and inhibited cell growth and colony formation of breast cancer cells with IC50 values in the low micromolar ranges. Enhanced radiosensitivity of triple-negative breast cancer cells was observed, with sensitiser enhancement ratios of 1.20-1.43, but with no evident radiosensitisation of luminal breast cancer cell lines. IQ9 upregulated protein expression of thioredoxin reductase in luminal but not in triple-negative breast cancer cells which may explain the observed differential radiosensitisation. This study provides important evidence of the roles of the thioredoxin system as an exploitable radiobiological target in breast cancer cells and highlights the potential therapeutic value of indolequinones as radiosensitisers. Kluwer Academic Publishers 2021 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/96589/1/ABSTRACT.pdf Abdullah, Nurul Akmaryanti and Inman, Martyn and Moody, Christopher J. and Storr, Sarah J. and Martin, Stewart G. (2021) Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer. Investigational New Drugs, 39. 1232 - 1241. ISSN 0167-6997; ESSN: 1573-0646 https://link.springer.com/article/10.1007/s10637-021-01106-5 10.1007/s10637-021-01106-5
spellingShingle Abdullah, Nurul Akmaryanti
Inman, Martyn
Moody, Christopher J.
Storr, Sarah J.
Martin, Stewart G.
Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
title Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
title_full Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
title_fullStr Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
title_full_unstemmed Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
title_short Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
title_sort cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer
url http://psasir.upm.edu.my/id/eprint/96589/
http://psasir.upm.edu.my/id/eprint/96589/
http://psasir.upm.edu.my/id/eprint/96589/
http://psasir.upm.edu.my/id/eprint/96589/1/ABSTRACT.pdf